Skip to main content

Cytovene Side Effects

Generic name: ganciclovir

Medically reviewed by Last updated on Nov 23, 2023.

Note: This document contains side effect information about ganciclovir. Some dosage forms listed on this page may not apply to the brand name Cytovene.

Applies to ganciclovir: powder for solution, solution.


Oral route (Capsule)

The clinical toxicity of ganciclovir includes granulocytopenia, anemia, and thrombocytopenia. Ganciclovir capsules are indicated only for prevention of cytomegalovirus (CMV) disease in patients with advanced HIV infection at risk for CMV disease, for maintenance treatment of CMV retinitis in immunocompromised patients, and for prevention of CMV disease in solid organ transplant recipients. Because ganciclovir is associated with a risk of more rapid rate of CMV retinitis progression, it should be used as maintenance treatment only in those patients for whom this risk is balanced by the benefit associated with avoiding daily IV infusions.

Intravenous route (Powder for Solution)

Granulocytopenia, anemia, thrombocytopenia, and pancytopenia have been reported in patients treated with ganciclovir sodium. Based on animal data and limited human data, ganciclovir sodium may cause temporary or permanent inhibition of spermatogenesis in males and suppression of fertility in females. Based on animal data, ganciclovir sodium has the potential to cause birth defects in humans. Based on animal data, ganciclovir sodium has the potential to cause cancers in humans.

Serious side effects of Cytovene

Along with its needed effects, ganciclovir (the active ingredient contained in Cytovene) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Medicines like ganciclovir can sometimes cause serious side effects such as blood problems; these are described below. Discuss these possible effects with your doctor.

Check with your doctor immediately if any of the following side effects occur while taking ganciclovir:

More common

For oral capsules and injection into the vein only

Less common

For oral capsules and injection into the vein only

For injection into the eye only

Other side effects of Cytovene

Some side effects of ganciclovir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to ganciclovir: intravenous powder for injection, intravenous solution, oral capsule.


The most commonly reported adverse events have included pyrexia, diarrhea, leukopenia, nausea, anemia, asthenia, headache, cough, dyspnea, abdominal pain, decreased appetite, and increased creatinine.[Ref]


Very common (10% or more): Leukopenia (up to 41%), anemia (up to 26%), neutropenia (up to 26%)

Common (1% to 10%): Thrombocytopenia, lymphadenopathy

Uncommon (0.1% to 1%): Bone marrow failure

Frequency not reported: Pancytopenia

Postmarketing reports: Hemolytic anemia, agranulocytosis, granulocytopenia[Ref]

During clinical trials for the treatment of CMV retinitis, neutropenia with absolute neutrophil count (ANC) less than 500, between 500 and 749, and 750 to less than 1000 mcL, was reported in 25%, 14%, and 26% of patients, respectively. Anemia with hemoglobin less than 6.5, between 6.5 and less than 8, and 8 to less than 9.5 g/dL was reported in 5%, 16%, and 26% of patients, respectively.

During clinical trials among transplant recipients receiving this drug for CMV prevention, neutropenia with absolute neutrophil count (ANC) less than 500, between 500 and 1000 mcL, and total ANC of 1000 mcL or less was reported in 4%, 3% and 7% of heart transplant recipients and 12%, 29%, and 41% of bone marrow transplant recipients, respectively. Thrombocytopenia with platelet counts less than 25,000 and between 25,000 and 50,000 mcL were reported in 3% and 5% and 32% and 25% of heart and bone marrow recipients, respectively. Total platelet count of 50,000 mcL or less was reported in 8% and 57% of heart and bone marrow recipients, respectively.[Ref]


Very common (10% or more): Diarrhea (up to 44%), vomiting 13%

Common (1% to 10%): Nausea, abdominal pain, constipation, flatulence, esophageal candidiasis, dysphagia, dyspepsia

Uncommon (0.1% to 1%): Mouth ulceration, abdominal distention, pancreatitis

Frequency not reported: Gastrointestinal perforation, eructation, dry mouth, pancreatitis

Postmarketing reports: Intestinal ulcer[Ref]


Elevated serum creatinine between greater than 1.5 and less than 2.5 mg/dL was reported in 14% of patients receiving 5 mg/kg/day for treatment of CMV retinitis; 2% experienced elevated serum creatinine of 2.5 mg/dL or greater.

Elevated serum creatinine between greater than 1.5 and less than 2.5 mg/dL was reported in 58%, 50%, and 43% of patients receiving this drug for CMV prevention in heart, and 2 bone marrow trials, respectively; 18%, 20%, and 0% experienced serum creatinine levels of 2.5 mg/dL or higher.[Ref]

Very common (10% or more): Elevated serum creatinine

Frequency not reported: Kidney failure, abnormal renal function, pleural effusion

Postmarketing reports: Renal tubular disorder, hemolytic uremic syndrome[Ref]


Frequency not reported: Urinary tract infection, urinary frequency, hematuria

Postmarketing reports: Testicular hypertrophy[Ref]


Frequency not reported: Hypersensitivity

Postmarketing reports: Anaphylactic reaction, allergic reaction[Ref]


Very common (10% or more): Retinal detachment (11%)

Common (1% to 10%): Eye hemorrhage, macular edema, vitreous floaters, eye pain

Frequency not reported: Visual impairment, vitreous disorders, eye pain, conjunctivitis

Postmarketing reports: Cataracts, dry eyes[Ref]

Retinal detachment has been observed both before and after initiation of therapy in patients with CMV retinitis; its relationship to therapy is unknown.[Ref]


Very common (10% or more): Tachycardia (16%), hypotension (11%)

Frequency not reported: Arrhythmias, chest pain, hypertension, phlebitis, vasodilation

Postmarketing reports: Cardiac arrest, conduction disorder, torsade de pointes, ventricular tachycardia, peripheral ischemia[Ref]

Cases of ventricular tachycardia associated with ganciclovir infusions in patients with AIDS have been reported, although it is known that HIV infection is associated with myocarditis, decreased left ventricular function, and in some cases, nonsustained ventricular tachycardia.[Ref]


Very common (10% or more): Hyperhidrosis (12%)

Common (1% to 10%): Pruritus, dermatitis, night sweats

Frequency not reported: Cellulitis, alopecia, dry skin, urticaria, rash, photosensitivity reaction

Postmarketing reports: Exfoliative dermatitis, Stevens-Johnson syndrome[Ref]


Common (1% to 10%): Increased alkaline phosphatase

Frequency not reported: Abnormal hepatic function tests, increased transaminases

Postmarketing reports: Cholelithiasis, cholestasis, hepatic failure, hepatitis[Ref]

Nervous system

Very common (10% or more): Headache (15%)

Common (1% to 10%): Peripheral neuropathy, tremor, dizziness, paresthesia, hypoesthesia, seizures, dysgeusia

Frequency not reported: Somnolence

Postmarketing reports: Dysesthesia, dysphasia, extrapyramidal disorder, facial paralysis, amnesia, anosmia, myelopathy, cerebrovascular accident, third cranial nerve paralysis, aphasia, encephalopathy, intracranial hypertension, facial palsy[Ref]


Postmarketing reports: Inappropriate antidiuretic hormone secretion, infertility[Ref]


Common (1% to 10%): Catheter infection, catheter sepsis, injection site inflammation,

other catheter related events

Frequency not reported: Injection site inflammation[Ref]


Very common (10% or more): Decreased appetite (14%), decreased blood magnesium (11%)

Common (1% to 10%): Decreased weight, anorexia

Frequency not reported: Hypocalcemia, hypokalemia, hyperglycemia

Postmarketing reports: Acidosis, hypercalcemia, hyponatremia, increased blood triglycerides[Ref]


Common (1% to 10%): Arthralgia, myalgia, back pain, muscle spasms

Frequency not reported: Leg cramps, myasthenia

Postmarketing reports: Arthritis, rhabdomyolysis[Ref]


Very common (10% or more): Cough (16%)

Common (1% to 10%): Pneumocystis carinii pneumonia, sinus congestion, rhinitis, dyspnea

Frequency not reported: Upper respiratory infection

Postmarketing reports: Bronchospasm, pulmonary fibrosis[Ref]


Very common (10% or more): Pyrexia (up to 48%)

Common (1% to 10%): Chills

Uncommon (0.1% to 1%): Deafness

Frequency not reported: Tinnitus, ear pain, fatigue, pain, malaise, asthenia, multiple organ failure

Postmarketing reports: Congenital anomaly, loss of sense of smell[Ref]


Very common (10% or more): Sepsis (15%), infection (13%)

Common (1% to 10%): Mycobacterium avium complex

Frequency not reported: Candida infections, influenza

Postmarketing reports: Vasculitis[Ref]


1. Product Information. Cytovene (ganciclovir). Genentech. 2002;PROD.

2. Whitely RJ. Ganciclovir: have we established clinical value in the treatment of cytomegalovirus infections? Ann Intern Med. 1988;108:452-4.

3. Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39:597-638.

4. SOCA Reseach Group, et al. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med. 1992;326:213-20.

5. Reed EC, Wolford JL, Kopecky KJ, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. Ann Intern Med. 1990;112:505-10.

6. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med. 1991;324:1005-12.

7. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601-7.

8. Sulecki M, Rosenfeld CS, Przepiorka D, et al. Treatment of ganciclovir-induced neutropenia with recombinant human GM-CSF. Am J Med. 1991;90:401-2.

9. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factor and outcome. Blood. 1997;90:2502-8.

10. Jabs DA. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The ganciclovir cidofovir cytomegalovirus retinitis trial. Am J Ophthalmol. 2001;131:457-67.

11. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in organ transplant patients. Drugs. 2004;64:2763-92.

12. Keven K, Basu A, Tan HP, et al. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc. 2004;36:3107-12.

13. Reischig T, Jindra P, Mares J, et al. Valacyclovir for Cytomegalovirus Prophylaxis Reduces the Risk of Acute Renal Allograft Rejection. Transplantation. 2005;79:317-324.

14. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of Oral Ganciclovir and Valganciclovir in Solid Organ Transplant Recipients. Transplantation. 2005;79:1477-1483.

15. Taegtmeyer AB, Halil O, Bell AD, Carby M, Cummins D, Banner NR. Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir. Transplantation. 2005;80:127-30.

16. Asano-Mori Y, Kanda Y, Oshima K, et al. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J Antimicrob Chemother. 2006;57:1004-7.

17. Cochrane AB. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients. Am J Health Syst Pharm. 2006;63(19 Suppl 5):S17-21.

18. Hayashi K, Mori J, Saito H, Hayashi T. Antiviral targets of a chromene derivative from Sargassum micracanthum in the replication of human cytomegalovirus. Biol Pharm Bull. 2006;29:1843-7.

19. Takami A, Mochizuki K, Ito S, et al. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation. Transplant Proc. 2007;39:237-9.

20. Tomonari A, Takahashi S, Ooi J, et al. Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after unrelated cord blood transplantation. Bone Marrow Transplant. 2007.

21. Figge HL, Bailie GR, Briceland LL, Kowalsky SF. Possible ganciclovir-induced hepatotoxicity in patients with aids. Clin Pharm. 1992;11:432-4.

22. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804-17.

23. Cochereau-Massin I, Lehoang P, Lautier-Frau M, et al. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in aids. Ophthalmology. 1991;98:1348-55.

24. Cohen AJ, Weiser B, Afzal Q, Fuhrer J. Ventricular tachycardia in two patients with aids receiving ganciclovir (DHPG). AIDS. 1990;4:807-9.

25. Marcollo Pini A, Kerl K, Kamarachev J, French LE, Hofbauer GF. Interstitial granulomatous drug reaction following intravenous ganciclovir. Br J Dermatol. 2008;158:1391-3.

26. Davis CL, Springmeyer S, Gmerek BJ. Central nervous system side effects of ganciclovir. N Engl J Med. 1990;322:933-4.

27. Hansen BA, Greenberg KS, Richter JA. Ganciclovir-induced psychosis. N Engl J Med. 1996;335:1397.

28. Schiff HB. More on ganciclovir-induced "psychosis". N Engl J Med. 1997;336:1190.

29. Ernst ME, Franey RJ. Acyclovir- and ganciclovir-induced neurotoxicity. Ann Pharmacother. 1998;32:111-3.

30. Georgiev OP, Lal SM, Gupta N, Ross G. Ganciclovir-associated hypercalcemia in a renal transplant patient. Int J Artif Organs. 1998;21:702-4.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.